1.21
price down icon3.20%   -0.04
after-market Handel nachbörslich: 1.22 0.01 +0.83%
loading
Schlusskurs vom Vortag:
$1.25
Offen:
$1.19
24-Stunden-Volumen:
247.78K
Relative Volume:
0.35
Marktkapitalisierung:
$38.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.3025
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
-13.57%
1M Leistung:
-14.79%
6M Leistung:
-76.95%
1J Leistung:
-86.73%
1-Tages-Spanne:
Value
$1.18
$1.26
1-Wochen-Bereich:
Value
$1.145
$1.42
52-Wochen-Spanne:
Value
$0.87
$9.98

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Firmenname
Outlook Therapeutics Inc
Name
Telefon
(609) 619-3990
Name
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-14
Name
Neueste SEC-Einreichungen
Name
OTLK's Discussions on Twitter

Vergleichen Sie OTLK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
OTLK
Outlook Therapeutics Inc
1.21 38.74M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-02 Herabstufung Chardan Capital Markets Buy → Neutral
2024-03-27 Hochstufung BTIG Research Neutral → Buy
2024-02-15 Hochstufung Chardan Capital Markets Neutral → Buy
2024-01-25 Hochstufung Guggenheim Neutral → Buy
2023-12-27 Hochstufung CapitalOne Equal Weight → Overweight
2023-08-31 Herabstufung Chardan Capital Markets Buy → Neutral
2023-08-31 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-30 Herabstufung BTIG Research Buy → Neutral
2023-08-30 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-08-30 Herabstufung CapitalOne Overweight → Equal Weight
2023-08-30 Herabstufung Guggenheim Buy → Neutral
2023-07-13 Eingeleitet CapitalOne Overweight
2023-04-03 Eingeleitet Guggenheim Buy
2023-02-06 Eingeleitet Cantor Fitzgerald Overweight
2022-10-31 Eingeleitet BTIG Research Buy
2022-09-13 Eingeleitet Chardan Capital Markets Buy
2019-09-11 Eingeleitet Ladenburg Thalmann Buy
2019-05-16 Eingeleitet Oppenheimer Outperform
2019-04-22 Eingeleitet Ascendiant Capital Markets Buy
Alle ansehen

Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025
pulisher
Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 01, 2025

Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire

Mar 01, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat

Feb 23, 2025
pulisher
Feb 21, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Feb 18, 2025
pulisher
Feb 18, 2025

Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat

Feb 18, 2025
pulisher
Feb 16, 2025

ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView

Feb 14, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Feb 14, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics Secures Funding and Board Restructures - MSN

Feb 14, 2025

Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):